Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications.
H.R.1350 - Camerons Law.
FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.1805 - Leos Law.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy.
H.R.830/S.1375 - HELP Copays Act.
H.R.5539 - ORPHAN Cures Act.
Duration: November 1, 2020
to
December 31, 2023
General Issues: Health Issues , Taxation/Internal Revenue Code
Spending: about $650,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives, Food & Drug Administration (FDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
Thorn Run Partners terminated an engagement in which they represented Harmony Biosciences on April 8.
Original Filing: 301547047.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications.
H.R.1350 - Camerons Law.
FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.1805 - Leos Law.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy.
H.R.830/S.1375 - HELP Copays Act.
H.R.5539 - ORPHAN Cures Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301539747.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications.
H.R.1350 - Camerons Law.
FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.1805 - Leos Law.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy.
H.R.830/S.1375 - HELP Copays Act.
H.R.5539 - ORPHAN Cures Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on Oct. 19, 2023.
Original Filing: 301509361.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications.
H.R.1350 - Camerons Law.
FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.1805 - Leos Law.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy.
H.R.830/S.1375 - HELP Copays Act.
H.R.5539 - ORPHAN Cures Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301484715.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications.
H.R.1350 - Camerons Law.
FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.1805 - Leos Law.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy.
H.R.830, S.1375 - The HELP Copays Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301463186.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications.
FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.1350, Camerons Law.
H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act.
H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act.
Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to Medicare Part D redesign.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436189.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders.
Drug pricing.
Access to non-controlled medications.
PDUFA Reauthorization.
H.R.6000 - Cures 2.0 Act.
FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169).
H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act.
H.R.6963 - Accelerated Approval Integrity Act of 2022.
H.R.2623 - Camerons Law.
H.R.7667 - Food and Drug Amendments of 2022.
S.4348 - FDASLA Act of 2022.
H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022.
H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to raising awareness of World Narcolepsy Day.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders.
Drug pricing.
Access to non-controlled medications.
PDUFA Reauthorization.
H.R.6000 - Cures 2.0 Act.
FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169).
H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act.
H.R.6963 - Accelerated Approval Integrity Act of 2022.
H.R.2623 - Camerons Law.
H.R.7667 - Food and Drug Amendments of 2022.
S.4348 - FDASLA Act of 2022.
H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022.
H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301420058.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders.
Drug pricing.
Access to non-controlled medications.
PDUFA Reauthorization.
H.R.6000 - Cures 2.0 Act.
FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169).
H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act.
H.R.6963 - Accelerated Approval Integrity Act of 2022.
H.R.2623 - Camerons Law.
H.R.7667 - Food and Drug Amendments of 2022.
S.4348 - FDASLA Act of 2022.
H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022.
H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Issues relatred to raising awareness of World Narcolepsy Day.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the development of therapies for rare diseases and sleep disorders.
Drug pricing.
Access to non-controlled medications.
PDUFA Reauthorization.
H.R.6000 - Cures 2.0 Act.
FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169).
H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act.
H.R.6963 - Accelerated Approval Integrity Act of 2022.
H.R.2623 - Camerons Law.
H.R.7667 - Food and Drug Amendments of 2022.
S.4348 - FDASLA Act of 2022.
H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022.
H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301394228.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the orphan drug tax credit.
Issues related to the Prescription Drug User Fee Act (PDUFA).
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301369810.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301330734.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases.
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313816.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases.
Issues regarding drug pricing.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the orphan drug tax credit.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301289728.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases.
Issues regarding drug pricing.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301262625.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases
Issues regarding drug pricing.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Thorn Run Partners lobbied for Harmony Biosciences , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241930.xml
Lobbying Issues
Issues related to the development of therapies for rare diseases.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
Thorn Run Partners filed a lobbying registration on Dec. 7, 2020 to represent Harmony Biosciences, effective Nov. 1, 2020.
Original Filing: 301227564.xml
Issue(s) they said they’d lobby about: Issues related to the development of therapies for rare diseases. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...